Repligen (NASDAQ:RGEN) Now Covered by Stephens

Analysts at Stephens assumed coverage on shares of Repligen (NASDAQ:RGEN - Get Free Report) in a report released on Tuesday, MarketBeat reports. The firm set an "overweight" rating and a $160.00 price target on the biotechnology company's stock. Stephens' price objective suggests a potential upside of 40.20% from the company's current price.

Other equities research analysts have also issued reports about the stock. Canaccord Genuity Group lowered their price target on shares of Repligen from $170.00 to $150.00 and set a "hold" rating on the stock in a report on Wednesday, April 16th. Evercore ISI lowered their price target on shares of Repligen from $140.00 to $130.00 and set an "in-line" rating on the stock in a report on Tuesday, July 8th. Wall Street Zen cut shares of Repligen from a "buy" rating to a "hold" rating in a report on Sunday, June 29th. Barclays began coverage on Repligen in a research report on Tuesday, June 24th. They set an "overweight" rating and a $150.00 target price on the stock. Finally, Royal Bank Of Canada cut their price objective on Repligen from $202.00 to $189.00 and set an "outperform" rating for the company in a research report on Wednesday, April 30th. Five research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat.com, Repligen currently has a consensus rating of "Moderate Buy" and a consensus price target of $169.92.

Repligen Trading Down 0.6%

Shares of NASDAQ:RGEN traded down $0.68 during trading hours on Tuesday, hitting $114.12. 1,507,183 shares of the company's stock traded hands, compared to its average volume of 730,730. The business has a fifty day moving average price of $124.27 and a 200-day moving average price of $138.20. The firm has a market capitalization of $6.41 billion, a P/E ratio of -253.60, a price-to-earnings-growth ratio of 3.32 and a beta of 1.11. The company has a debt-to-equity ratio of 0.27, a current ratio of 6.79 and a quick ratio of 5.79. Repligen has a 1 year low of $102.97 and a 1 year high of $182.52.

Repligen (NASDAQ:RGEN - Get Free Report) last released its quarterly earnings results on Tuesday, April 29th. The biotechnology company reported $0.39 EPS for the quarter, topping the consensus estimate of $0.35 by $0.04. Repligen had a positive return on equity of 4.53% and a negative net margin of 3.93%. The firm had revenue of $169.17 million during the quarter, compared to analyst estimates of $163.65 million. During the same period in the previous year, the company posted $0.28 EPS. The business's revenue for the quarter was up 10.4% compared to the same quarter last year. Equities analysts expect that Repligen will post 1.72 earnings per share for the current year.

Institutional Investors Weigh In On Repligen

A number of institutional investors and hedge funds have recently bought and sold shares of RGEN. Price T Rowe Associates Inc. MD raised its stake in Repligen by 6.0% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 7,566,093 shares of the biotechnology company's stock valued at $962,711,000 after acquiring an additional 430,039 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of Repligen by 1.1% during the fourth quarter. Vanguard Group Inc. now owns 5,101,090 shares of the biotechnology company's stock worth $734,251,000 after purchasing an additional 56,723 shares during the last quarter. Champlain Investment Partners LLC lifted its holdings in shares of Repligen by 8.6% during the fourth quarter. Champlain Investment Partners LLC now owns 1,543,530 shares of the biotechnology company's stock worth $222,176,000 after purchasing an additional 122,595 shares during the period. Alliancebernstein L.P. grew its position in Repligen by 1.3% in the 1st quarter. Alliancebernstein L.P. now owns 1,024,180 shares of the biotechnology company's stock valued at $130,317,000 after buying an additional 13,284 shares during the last quarter. Finally, Conestoga Capital Advisors LLC raised its position in Repligen by 3.4% during the 1st quarter. Conestoga Capital Advisors LLC now owns 980,247 shares of the biotechnology company's stock worth $124,727,000 after buying an additional 32,665 shares during the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.